###### Strengths and limitations of this study

-   Our findings were based on a community-based metabolomics study with paired design, and strict quality assurance and quality control.

-   Multivariable conditional logistic models were used to examine the association between specific levels of amino acids (AAs) and arsenic-induced skin lesions (AISL), and the receiver operator characteristic analysis was applied to evaluate the feasibility of AAs to distinguish patients with AISL from their counterparts.

-   Although AAs were determined by untargeted metabolomics approach, which can assess a large number of metabolites precisely and efficiently, only relative levels of AAs could be obtained instead of their accurate quantitative concentration.

-   Based on a case--control study, the findings only revealed the association between AAs and the odds of AISL rather than confirming their causal relationship.

-   The participants were mainly chronically exposed to arsenic via drinking water, which may limit the findings extrapolated to another arsenic exposure population via food or other routes.

Introduction {#s1}
============

Chronic arsenic exposure via drinking water is widely considered a global health concern affecting several people worldwide. This exposure may cause various human health issues such as cardiovascular diseases, diabetes and cancer.[@R1] With the industrial boom and considerable increase in global water pollution including arsenic contamination in the past, the prevalence and burden of arsenic-induced health damage will continue to increase. The skin has been confirmed as one of the most common and susceptible targets of arsenic-induced health effects. Cutaneous skin lesions are typical signs of arsenicosis after persistent and long-term arsenic exposure. These lesions are characterised by hyperkeratosis and hyperpigmentation. Considerable evidence of the prevalence of arsenic-induced skin lesions (AISL) has been reported in several countries.[@R3]

As AISL are widely accepted as the major early manifestation of arsenic toxicity[@R6] and may be an indicator of susceptibility to more serious arsenic-induced health hazards,[@R7] it is critical to identify people who are at risk as early as possible to prevent the onset or delay the progression of serious health problems. Several possible mechanisms such as genetic differences,[@R8] oxidative stress[@R9] and epigenetic dysregulation[@R10] may explain arsenic poisoning. Previous studies also suggested that arsenic methylation in vivo is associated with metabolic syndrome.[@R11]

Amino acids (AAs) are the 'basic unit' of all proteins and are necessary to maintain health. Some AAs are important regulators of key metabolic pathways and also help in maximising food utilisation, enhancing protein accretion and improving health.[@R13] Abnormal metabolism of AAs can disturb homeostasis in the body, impair growth and development and even cause death.[@R15] Thus, the levels of serum AAs may be important indicators of metabolic status and disease condition. As powerful tools in system biology research, metabolomics approaches are beneficial for unbiased monitoring of changes in endogenous metabolism-related physiological processes, providing integrative information on distinct features across multiple functional levels. These methods capture the core attributes responsible for various phenotypes, which are particularly important in understanding the relevant pathophysiological changes of a disease and its status, and in identifying novel biomarkers for risk screening, diagnosis, treatment and prognosis of important human diseases.[@R16]

Animal experiments and epidemiological studies have reported obvious arsenic-related metabolomics perturbations.[@R19] These results suggest that the relationship between specific metabolites and arsenic-induced health lesions should be investigated. However, only a few studies have been conducted to comprehensively examine the metabolic mechanism relevant to AISL, particularly for AA metabolism. This study was conducted to quantitatively examine the association of several specific AAs with AISL and their ability to identify AISL.

Methods {#s2}
=======

Study population {#s2-1}
----------------

The study data were originally obtained from a randomised, double-blind and placebo-controlled clinical trial performed in 2010, in which all subjects were randomly selected by permuted block randomisation from a single rural area in which a population was chronically exposed to low-level arsenic drinking water, had similar lifestyles and were influenced by similar environmental factors. Information on the inclusion and exclusion criteria of the participants can be found in our previous study.[@R21] Strictly following the criteria of arsenicosis,[@R22] AISL was diagnosed as the presence of arsenic-induced keratosis, hyperpigmentation or depigmentation by a physician from the Wenzhou Medical University at the beginning of the trial. This was a matched case--control study (1:1 matching). Among 450 residents aged 18--79 years enrolled in the previous trial, 56 were diagnosed as having AISL and selected as the case group. Another 56 participants without AISL matched by gender and age (±1 year) from the same population were evaluated as controls. The inclusion criteria were subjects who underwent a metabolomic test. Unmatched participants and those without serum metabolites data were excluded.

Data collection and assessment {#s2-2}
------------------------------

Information on age, gender, exposure year, body mass index, smoking, alcohol consumption and education level, among other factors, was collected using a standardised questionnaire. Blood and urine samples were also collected at the time of participants' enrolment. The detailed methods for analysing blood and urine samples and assessment methods for clinical variables including fasting plasma glucose (FPG), serum urea nitrogen, serum folate, total homocysteine, total cholesterol, triglycerides (TG), high-density lipoprotein, low-density lipoprotein (LDL) and others have been published previously.[@R21] Various urinary arsenic species were separated and detected by high-performance liquid chromatography coupled mass spectrometry system.[@R23] The species of arsenic in urine samples consisted of inorganic arsenic (iAs, \[iAs^Ⅲ^ plus iAs^Ⅴ^\]), monomethyl arsenate (MMA, \[MMA^Ⅲ^ plus MMA^Ⅴ^\]) and dimethyl arsenate (DMA, \[DMA^Ⅲ^ plus DMA^Ⅴ^\]). All arsenic species were corrected by creatinine. The total arsenic (tAs) was the sum of iAs, MMA and DMA. The percentages of arsenic species were defined as follows: iAs%=iAs/tAs\*100%, MMA%=MMA/tAs\*100% and DMA%=DMA/tAs\*100%, respectively.

Ultra-high-performance liquid chromatography--quadrupole time-of-flight mass spectrometry metabonomic profiling {#s2-3}
---------------------------------------------------------------------------------------------------------------

Serum samples were thawed to 4°C, and then 600 µL of a mixture of 90% acetonitrile and 10% water was added to each sample (200 µL in microcentrifuge tubes). The samples were vigorously mixed for 20 s and then centrifuged for 5 min at 12 000 g (20°C). Four hundred microlitres of each supernatant were transferred to a new tube and dried in a vacuum concentrator centrifuge. The dried samples were re-suspended in 130 µL of water (containing 15% acetonitrile), mixed vigorously for 20s centrifuged as described above. Two microlitres of the supernatant were collected for analysis. Serum metabolic profile was acquired using ACQUITY UPLC/Xevo G2 QTof/MS^E^ (Waters Corp., Milford, MA, USA). Chromatographic separation was performed at 50°C using a Waters HSS T3 column (2.1 mm × 100 mm, 1.7 µm; Milford, MA, USA) at a flow rate of 0.4 mL/min. The mobile phase was a mixture of (A) H~2~O with 0.1% formic acid and (B) methanol with 0.1% as follows: 0 min with 100% A and 0% B, 1 min with 100% A and 0% B, 8 min with 0%A and 100% B, and 13 min with 0% A and 100% B. The mass spectrometer was operated under both electrospray ionisation positive-ion (ESI^+^) mode and negative-ion (ESI^−^) mode. The scan range was 50--1200 m/z. The capillary voltage was set to 3000 and 2500 V, respectively. The desolvation flow rate was 800 L/h at 350°C. Argon was used as the collision gas, and the collision energy was adjusted from 10 to 40 eV in each analysis. Quantum clustering samples were prepared by pooling aliquots of each sample and used to reflect the reliability of further metabolomics analysis. After peak deconvolution, alignment, integration and normalisation, the data including retention time, mass to charge ratio (m/z) and peak intensity were extracted from raw chromatograms using Progenesis QI V.2.0 (Waters Corp.). MS/MS was performed to determine metabolite levels using MarkerLynx Applications Manager V.4.1 (Waters Corp.).

Distinct metabolite identification {#s2-4}
----------------------------------

The peak intensities of metabolites for the 56 pairs of subjects were acquired and imported into MetaboAnalyst V.4.0 (<http://www.metaboanalyst.ca/>) for statistical analyses. A partial least squares-discriminant analysis (PLS-DA), which is a supervised and well-accepted pattern recognition approach, was used to differentiate between the cases and controls. The false discovery rate (FDR)-adjusted p value in univariate analysis was determined to reduce the potential effect of false-positive results. The criteria used to select metabolites included variable importance in projection (VIP) scores\>1 using PLS-DA and a crude or FDR-adjusted p value \<0.05 using Wilcoxon signed-rank test. We identified 70 extracted small molecular metabolites linked to the recognition of AISL. The Human Metabolome Database (<http://www.hmdb.ca>) was used to identify the metabolites, which include four AA metabolites (phenylalanine, tryptophan, leucine and phenylalanylphenylalanine).

Statistical analysis {#s2-5}
--------------------

The normality of continuous data was assessed using both QQ-plots and Shapiro-Wilk test. The data of cases and controls were analysed using paired t-test if they showed a normal or similar normal distribution. Otherwise, Wilcoxon signed-rank test was used. Differences in the proportion of categorical variables between the two groups were evaluated using McNemar-Bowker test. We first used locally weighted scatterplot smoothing models to estimate the 'real' relationship between serum AA levels and the probability of AISL. Next, multivariable conditional logistic regression models were used to examine the association between contributing AA levels and AISL after adjusting for potential confounding factors. The individual effects of AA metabolites on the risk of AISL were quantified separately using the OR and 95% CI as follows: with AAs as a categorical variable (quartiles) and as a continuous variable (scaled to an IQR). Variables with a p value less than 0.2 in the comparison between two groups were selected as potential confounders. This approach has been widely used in many studies, particularly for small sample size. The variance inflation factor (VIF) was used to examine the potential collinearity among variables. As too many covariates in a multiple regression model can lead to overfitting,[@R24] we selected no more than four variables as confounding factors to decrease the potential of overfitting when assessing the association between AAs and AISL. Furthermore, as distinct metabolites may be highly related to each other, collinearity should be considered. Thus, we used the VIF based on VIF package of R software to detect potential collinearity among the AAs. A VIF greater than 1.5 is considered to indicate collinearity in the model, and the associated variable is removed. The combined effect of relevant AAs on AISL was also determined using a multivariable logistic regression model. A receiver operator characteristic (ROC) analysis was applied to evaluate the value and feasibility of AAs as potentially sensitive and specific biomarkers for recognising AISL. Data management, analysis and figure drawing were performed using R V.3.4.4 (Copyright 2018 The R Foundation for Statistical Computing). All tests were two-sided and the results with p values\<0.05 were considered to indicate significance.

Patient and public involvement {#s2-6}
------------------------------

The present study was designed as an observational study, and as such patients and the public were not involved in the planning, recruitment and conduct of this study. All participants were informed about the purpose of this study and signed informed consent at the beginning of the study. The results of this study have not yet been disseminated to the participants.

Results {#s3}
=======

[Table 1](#T1){ref-type="table"} summarises the general characteristics of the study population. Comparisons of the demographic data, clinical features and urinary arsenic species in the 56 pairs of subjects are presented in [table 1](#T1){ref-type="table"}. The median (first and third quartiles) age of AISL population was 50.30 (44.70 and 58.70) for the cases and 50.40 (44.60 and 58.70) years for the controls. Both groups contained the same proportion of females (58.93%), and there was no significant difference in urinary arsenic levels between the two groups. More than half of the subjects had no history of smoking or alcohol consumption. The serum TG level in subjects with AISL was significantly lower than that in the controls (p=0.041). Other variables were similar between the subjects with AISL and controls (p\>0.05). This indicates that the participants in the two groups were comparable.

###### 

Demographic characteristics of the study population\*

  Variables                            AISL (n=56)               Non-AISL (n=56)          P value
  ------------------------------------ ------------------------- ------------------------ ---------
  Clinical characteristics                                                                
   Age (years)                         50.30 (44.70, 58.70)      50.40 (44.60, 58.70)     0.425
   Exposure year (years)               48.19±11.53               47.62±10.97              0.489
   Body mass index (kg/m^2^)           24.12±3.14                23.91±2.86               0.697
   Fasting plasma glucose (mmol/L)     4.89 (4.60,5.25)          5.12 (4.53,5.40)         0.137
   Folate (ng/mL)                      4.00 (3.20,5.10)          4.25 (3.35,5.40)         0.392
   Total homocysteine (µmol/L)         12.30 (10.32, 16.50)      12.67 (11.21, 14.69)     0.961
   Blood urea nitrogen (mmol/L)        6.45 (5.42, 7.69)         6.84 (5.36, 8.80)        0.603
   Total cholesterol (mmol/L)          4.58 (4.10, 5.69)         4.65 (3.96, 5.95)        0.904
   Triglycerides (mmol/L)              1.41 (0.90, 1.74)         1.45 (1.09, 2.29)        0.041
   High-density lipoprotein (mmol/L)   1.19±0.34                 1.16±0.31                0.675
   Low-density lipoprotein (mmol/L)    3.04±0.80                 3.25±0.84                0.110
   Women (\# (%))                      33 (58.93)                33 (58.93)               1.000
   Cigarette smoking (\# (%))          20 (35.71)                22 (39.29)               0.696
   Alcohol consumption (\# (%))        17 (30.91)                21 (37.50)               0.464
   Illiteracy (\# (%))                 21 (37.50)                15 (25.00)               0.252
  Urinary arsenic species†                                                                
   iAS%                                12.26 (8.13, 14.68)       12.31 (10.04, 16.54)     0.148
   MMA%                                24.68 (20.11, 29.68)      25.85 (20.90, 31.66)     0.420
   DMA%                                61.84 (56.62, 71.01)      61.84 (47.85, 64.99)     0.096
   tAs (µg/g creatinine)               140.93 (104.41, 208.53)   186.77 (80.11, 217.30)   0.445

\* iAS (iAs^Ⅲ^+iAs^Ⅴ^); MMA (MMA^Ⅲ^+MMA^Ⅴ^); DMA (DMA^Ⅲ^+DMA^Ⅴ^); tAs: As^Ⅲ^+iAs^Ⅴ^+MMA+ DMA; iAs%=iAS/tAs\*100%; MMA%=MMA/tAs\*100% and DMA%=DMA/tAs\*100%.

† The variables met normal distribution was described with mean±SD; otherwise, median (first quartile, third quartile) was used to describe their features. Number of cases (percentage) was used to describe the proportion of categorical variables between the two groups.

ALSL, arsenic-induced skin lesions; DMA, dimethyl arsenate; iAS, inorganic arsenic; MMA, monomethyl arsenate; tAs, total arsenic.

[Table 2](#T2){ref-type="table"} shows that the four AAs, with an FDR-adjusted p value of \<0.05 and VIP of \>1, were significantly lower in the cases than in the controls. Two were aromatic amino acids (AAAs) identified as phenylalanine and tryptophan, one was a branched-chain amino acid (BCAA) identified as leucine, and the last AA was phenylalanylphenylalanine. The individual associations of AAs with AISL are presented in [figure 1](#F1){ref-type="fig"}, which shows obvious 'dose--response' relationships.

###### 

Distinct metabolites in population with arsenic-induced skin lesions and their counterparts

  ------------------------------------------------------------------------------------------------------------------
  Serum amino acid metabolites   Retention time (min)   Mass-to-\      VIP value   P values\*   Adjusted p values†
                                                        charge ratio                            
  ------------------------------ ---------------------- -------------- ----------- ------------ --------------------
  Phenylalanine                  3.402                  166.087        1.508       \<0.001      0.009

  Tryptophan                     3.886                  203.082        1.046       0.003        0.014

  Leucine                        2.642                  132.102        1.014       0.001        0.020

  Phenylalanylphenylalanine      5.048                  313.155        1.833       0.004        0.033
  ------------------------------------------------------------------------------------------------------------------

\*Wilcoxon signed-rank test

†Adjusted by false discovery rate.

VIP, variable importance in the projection.

![Association between the peak intensity of tryptophan and phenylalanine and arsenic-induced skin lesions based on multivariable locally weighted regression models. (A) Tryptophan; (B) phenylalanine; (C) leucine and (D) phenylalanylphenylalanine.](bmjopen-2018-025336f01){#F1}

[Table 3](#T3){ref-type="table"} shows that participants in the third and fourth quartiles of the four specific AAs were significantly linked to decreased odds of AISL after adjusting for FPG, LDL, TG and DMA%, as compared with that of their lowest quartiles. The category boundaries of the quartiles are shown in [Online supplementary table S1](#SP1){ref-type="supplementary-material"}. Significant linear trends were detected between AISL and the four serum AAs. The same linear negative association between AISL and per IQR increase in the four serum AAs was observed when these AAs were considered as continuous variables in the present study.
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###### 

Relationship of amino acid levels with the odds of arsenic-induced skin lesions\*

  Amino acids                 N     Cases (%)    Crude                 Adjusted†                         
  --------------------------- ----- ------------ --------------------- ----------- --------------------- -------
  Tryptophan                                                                                             
   Per IQR                    112   56(50)       0.48 (0.27 to 0.84)   0.011       0.48 (0.27 to 0.86)   0.013
   Quartiles                                                                                             
   Q~1~                       28    20 (71.40)   1.00 (1.00 to 1.00)   Ref.        1.00 (1.00 to 1.00)   Ref.
   Q~2~                       28    15 (53.60)   0.50 (0.16 to 1.54)   0.225       0.56 (0.16 to 1.98)   0.370
   Q~3~                       28    10 (35.70)   0.12 (0.03 to 0.53)   0.005       0.12 (0.02 to 0.60)   0.010
   Q~4~                       28    11 (39.30)   0.19 (0.05 to 0.71)   0.014       0.21 (0.05 to 0.84)   0.028
   P for trend                                                         0.008                             0.012
  Phenylalanine                                                                                          
   Per IQR                    112   56(50)       0.57 (0.36 to 0.91)   0.019       0.56 (0.33 to 0.94)   0.028
   Quartiles                                                                                             
   Q~1~                       28    20 (71.40)   1.00 (1.00 to 1.00)   Ref.        1.00 (1.00 to 1.00)   Ref.
   Q~2~                       28    19 (67.90)   0.79 (0.22 to 2.82)   0.712       0.70 (0.18 to 2.76)   0.609
   Q~3~                       28    8 (28.60)    0.18 (0.05 to 0.66)   0.010       0.20 (0.05 to 0.77)   0.019
   Q~4~                       28    9 (32.10)    0.25 (0.08 to 0.79)   0.018       0.20 (0.05 to 0.75)   0.017
   P for trend                                                         \<0.001                           0.001
  Leucine                                                                                                
   Per IQR                    112   56(50)       0.45 (0.25 to 0.82)   0.019       0.43 (0.21 to 0.86)   0.016
   Quartiles                                                                                             
   Q~1~                       28    21 (75.00)   1.00 (1.00 to 1.00)   Ref.        1.00 (1.00 to 1.00)   Ref.
   Q~2~                       28    14 (50.00)   0.33 (0.11 to 1.03)   0.057       0.31 (0.10 to 1.01)   0.052
   Q~3~                       28    11 (39.30)   0.22 (0.07 to 0.68)   0.009       0.22 (0.07 to 0.73)   0.014
   Q~4~                       28    10 (35.70)   0.19 (0.06 to 0.59)   0.004       0.19 (0.06 to 0.65)   0.008
   P for trend                                                         0.003                             0.007
  Phenylalanylphenylalanine                                                                              
   Per IQR                    112   56(50)       0.62 (0.36 to 1.04)   0.070       0.71 (0.41 to 1.24)   0.227
   Quartiles                                                                                             
   Q~1~                       27    21 (77.80)   1.00 (1.00 to 1.00)   Ref.        1.00 (1.00 to 1.00)   Ref.
   Q~2~                       29    14 (48.30)   0.16 (0.03 to 0.75)   0.021       0.14 (0.03 to 0.73)   0.019
   Q~3~                       28    9 (32.10)    0.08 (0.02 to 0.39)   0.002       0.09 (0.02 to 0.52)   0.007
   Q~4~                       28    12 (42.90)   0.12 (0.02 to 0.57)   0.008       0.11 (0.02 to 0.66)   0.016
   P for trend                                                         0.006                             0.023

\*Adjusted for plasma glucose, low-density lipoprotein, triglyceride and urinary dimethyl arsenate.

†Values are ORs (95% CIs) for arsenic-induced skin lesions from conditional logistic regression. Q~1~: the first quartile; Q~2~: the second quartile; Q~3~: the third quartile; Q~4~: the fourth quartile.

As these four specific AAs were significantly or marginally significantly associated with the odds of AISL, we examined their combined effects on AISL. However, analysis of potential collinearity revealed that among the four specific AAs, both tryptophan and phenylalanine had the smallest VIF value (VIF=1.04), and no obvious collinearity existed ([Online supplementary table S2](#SP1){ref-type="supplementary-material"}). Thus, we mainly focused on tryptophan and phenylalanine to assess the combined effects of AAs on AISL and only presented the results associated with these two AAs in the present study. To avoid the effects of insufficient power because of unreasonable grouping of the results, we classified both tryptophan and phenylalanine into two categories, according to the cut-off values of their mass spectrum peak area based on the ROC analysis, respectively. The higher levels of these two serum AAs were defined as equal to or higher than the cut-off values, whereas the lower categories were considered as less than the associated values.

[Table 4](#T4){ref-type="table"} shows the combined effects of tryptophan and phenylalanine levels on AISL after considering the collinearity of variables in the model. The proportions of AISL were 74.3%, 60.0%, 50.0% and 18.2% for participants with lower levels of both tryptophan and phenylalanine (category A), with higher level of tryptophan and lower level of phenylalanine (category B), with lower level of tryptophan and higher level of phenylalanine (category C), and higher levels of both tryptophan and phenylalanine (category D), respectively. An obvious decrease in the probability of AISL was observed among these four categories. Compared with that of category A, the adjusted OR (95% CI) for participants in categories B, C and D was 0.49 (0.15 to 1.63), 0.32 (0.10 to 1.02) and 0.08 (0.02 to 0.25), respectively. Subjects with higher levels of both tryptophan and phenylalanine had the lowest odds of AISL, which significantly decreased by 92% (OR=0.08; 95% CI 0.02 to 0.25; p\<0.001), after adjusting for the effects of some potential confounding factors. This suggests that tryptophan and phenylalanine are jointly associated with AISL, although no significant interaction between the two AAs and occurrence of AISL was observed (p=0.419).

###### 

Joint association between tryptophan and phenylalanine levels with arsenic-induced skin lesions

  ------------------------------------------------------------------------------------------------------------------------------------
  Tryptophan\         Phenylalanine\      N    Cases (%)   Crude                 Adjusted†                                   
  \<cut-off value\*   \<cut-off value\*                                                                                      
  ------------------- ------------------- ---- ----------- --------------------- --------------------- --------------------- ---------
  Yes                 Yes                 35   26 (74.3)   1.00 (1.00 to 1.00)   Ref.                  1.00 (1.00 to 1.00)   Ref.

  No                  Yes                 20   12 (60.0)   0.52 (0.16 to 1.68)   0.273                 0.49 (0.15 to 1.63)   0.244

  Yes                 No                  24   12 (50.0)   0.35 (0.12 to 1.04)   0.059                 0.32 (0.10 to 1.02)   0.053

  No                  No                  33   6 (18.2)    0.08 (0.02 to 0.25)   \<0.001               0.08 (0.02 to 0.25)   \<0.001

  Interaction                                              0.320                 0.49 (0.09 to 2.78)   0.419                 
  ------------------------------------------------------------------------------------------------------------------------------------

\*Adjusted for plasma glucose, low-density lipoprotein, triglyceride and urinary dimethyl arsenate.

†Cut-off value was determined using receiver operator characteristic analysis.

[Table 5](#T5){ref-type="table"} shows that, based on the ROC analysis, both serum tryptophan and phenylalanine levels might be potential biomarkers in distinguishing AISL from a chronic arsenic exposure population (p=0.0020 and p=0.0017). The area under the curve (AUC) and its related 95% CI, sensitivity, specificity, positive predictive value and negative predictive value were 0.67 (0.57 to 0.77), 69.64%, 62.50%, 65.00% and 67.31% for tryptophan, and 0.70 (0.60 to 0.80), 69.64%, 69.64%, 69.64% and 69.64% for phenylalanine, respectively. The AUC (95% CI), sensitivity, specificity, positive predictive value and negative predictive value of the combination of them were 0.72 (0.62 to 0.81), 76.79%, 58.93%, 65.15% and 71.74% respectively. Our results suggest that these two AAs could be either individually or jointly used as indicators of AISL identification.

###### 

Combination of diagnostic indicators and ROC analysis results\*

  Indicators      AUC (95% CI)          Sensitivity, %   Specificity, %   Predict^+^, %   Predict^−^, %   P value
  --------------- --------------------- ---------------- ---------------- --------------- --------------- ---------
  Tryptophan      0.67 (0.57 to 0.77)   69.64            62.50            65.00           67.31           0.002
  Phenylalanine   0.70 (0.60 to 0.80)   69.64            69.64            69.64           69.64           0.002
  Combined†       0.72 (0.62 to 0.81)   76.79            58.93            65.15           71.74           \<0.001

\*The sensitivities, specificity, positive predictive value and negative predictive value were calculated at their best cut-off points; Predict+: positive predictive value; Predict−: negative predictive value.

†Combined: tryptophan and phenylalanine. The combination is modelled according to the formula β~1~X~1~ + β~2~X~2~, with X~j~ denoting the standardised value for the j^th^ amino acid and βj denoting the regression coefficient from the logistic regression model.

AUC, area under the curve; ROC, receiver operator characteristic.

Discussion {#s4}
==========

In the present study, the association of serum tryptophan and phenylalanine, screened in our previous non-targeted metabolomics study using ultra-high-performance liquid chromatography-tandem mass spectrometer, with AISL and their ability to indicate AISL occurrence were quantitatively evaluated in individual and joint modes. Our results clearly showed that AISL was significantly and negatively associated with serum tryptophan and phenylalanine levels in a chronically arsenic-exposed population via drinking water. Participants with a higher level of both AAs showed the lowest odds of AISL. These two AAs may be useful as indicators of AISL.

The probability of initiation and development of AISL is affected by numerous factors including age, gender, lifestyles, arsenic exposure and metabolism. These factors may be important confounding factors and largely affect our results. To adjust for the effects of these co-factors, we first selected all participants using permuted block randomisation from a single rural area in which the population was chronically exposed to arsenic in the same route, had a similar lifestyle and was influenced by similar environmental factors. Second, the cases and controls were matched by gender and age (±1 year). All of these may be the reason for the so many potential confounders including arsenic exposure, which did not differ significantly between the cases and controls.

Participants enrolled in the current study were chronically exposed to arsenic via drinking water. The geometric mean (GM) and its related 95% CI of urinary iAs/creatinine and tAs/creatinine in this population were 17.49 (14.90 to 20.53) µg/g and 147.20 (129.00 to 167.97) µg/g, respectively. They were much higher than those in the 20 µg/L exposed to arsenic via drinking water (GM (95% CI): 0.4 (0.3 to 0.5) µg/g for iAs and 9.1 (6.5 to 12.7) µg/g for tAs), while obviously lower than those in the 90 µg/L exposed group (GM (95% CI): 39.4 (31.4 to 49.6) µg/g for iAs and 248.7 (208.8 to 296.3) µg/g for tAs).[@R25] An available report has shown that AISL cannot be completely cured even though medical technology has already made great progress.[@R26] Therefore, it is crucial to identify those who are most likely to progress to overt arsenic damages including AISL among people at risk as early as possible. Metabolomics study, which mainly focuses on thoroughly assessing the variation in metabolites possibly linked to disease occurrence and development, has been widely utilised to help understand the pathogenesis of diseases because of its relevance to the phenotypes compared with other omics study.[@R27] Moreover, mathematical modelling to assess the linkage between small molecular metabolites and arsenic toxicity has advanced.[@R28] Developing a simple and interpretable modelling approach for the early detection of arsenic-induced lesions is of great theoretical value and realistic meaning,[@R29] although it might be difficult due to population-specific complexities and effect of some potential unmeasured covariates such as diet and genetic determinants.

Previous studies have reported that gene--gene and gene--environment interactions are involved in arsenicosis through toxicological mechanisms including genomic instability[@R30] and oxidative stress.[@R31] Skin hyperpigmentation and palmoplantar hyperkeratosis may be biomarkers for long-term arsenic exposure and useful for identifying differences in metabolites associated with phenotypes. Metabolite analysis may improve the understanding and identification of AISL. An animal study revealed that examining the disruption in AA metabolism on arsenic exposure in rats may be beneficial for understanding arsenic toxicity.[@R32] In our previous population-based metabolomics study, we found that serum metabolite alterations were significantly related to the risk of arsenic-induced health damages. In the present study, we found that some BCAAs or AAAs were significantly related to AISL occurrence. Several studies across numerous ethnic backgrounds support the use of BCAAs including leucine, isoleucine, valine and AAA profiles such as those of phenylalanine, tryptophan and tyrosine as biomarkers for identifying metabolic diseases.[@R27] Zhou *et al* reported that arsenic-induced transformed cells had altered metabolite profiles including downregulation of leucine, tryptophan and phenylalanine in the skin lesion group.[@R34] Consistent with these findings, the levels of two serum AAAs (tryptophan and phenylalanine) were significantly associated with AISL in our study.

Normal metabolism of AAs is necessary for whole-body homeostasis, growth and development, and health.[@R15] Studies have reported that changes in the availability of AAAs affect cell signalling, gene expression, brain function and neuroendocrine function.[@R35] Tryptophan, an AA metabolism-related biomarker, is a sensitive and specific indicator of oxidation. Tryptophan metabolism in mammals is a physiological means of preserving immune homeostasis associated with oxidative stress and inflammation.[@R36] Additionally, phenylalanine can be transformed into specific neurotransmitters such as dopamine and epinephrine via the action of related enzymes. Wu *et al* [@R38] reported that arsenic exposure can lead to neurotransmitter metabolism, which may explain the reduction in phenylalanine. Furthermore, as a peptide-bound phenylalanine, phenylalanylphenylalanine has been reported to affect protein synthesis and secretion,[@R39] indicating a relationship between endothelium dysfunction and phenylalanine metabolism disorder. The relationship between AA metabolism and AISL remains unclear. The notable alteration of tryptophan and phenylalanine in this study indicates the occurrence of metabolic disorders due to arsenic exposure. These results are also beneficial for understanding the effects of arsenic toxicity and importance of early identification of exposure for delaying the progression of various arsenic-induced lesions, including AISL.

The main strength of this study is that the findings were based on a community-based, long-term arsenic exposure cohort with well-designed quality assurance and quality control throughout the study. However, there were some limitations to this study. First, although the untargeted metabolomics approach can assess a large amount number of metabolites precisely and efficiently, it only provided relative levels of AAs instead of their accurate quantitative concentration. Second, these findings were mainly based on a case--control study, which only reveals the association between AA metabolism and the odds of AISL rather than confirming their causal relationship. Furthermore, the study included 56 AISL cases-matched and 56 non-AISL controls and the sample size might be potentially insufficient. Although metabolomics studies usually have a sample size of no more than 40 cases in each group,[@R40] our study may be under-powered and thus larger studies are needed in the future. Besides, as it is suggested that the ratio of approximately 10--15 observations per predictor in a logistic regression model will produce reasonably stable estimations,[@R24] we selected only four covariates in the models due to the small sample size and these results need to be confirmed in further studies. Finally, the participants were mainly exposed to arsenic via drinking water, which would limit the findings from being extrapolated to other arsenic exposure populations via food and other routes. Therefore, additional elaborate population-based studies are needed to verify our findings.

In conclusion, specific AAs may be linked to AISL and AA metabolism may play an important role in early AISL identification. Additional studies are needed to confirm our findings.
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